These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 37572120

  • 1. Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients.
    Ruan M, Chang C, Sun J, Liu L, Wang L, Lei B, Yan H, Zhang H, Xie W, Wang Y.
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14493-14507. PubMed ID: 37572120
    [Abstract] [Full Text] [Related]

  • 2. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.
    Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, Liao T, Liu S, Lan X, Liao S, Geng W, Jin Y.
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [Abstract] [Full Text] [Related]

  • 3. Correlation of FDG PET/CT, tumor markers and Ki-67 index with EGFR mutation or positive ALK expression in patients with non-small cell lung cancer.
    Wang HC, Wang ZM, Hu WD, Liang XQ, Cui LL.
    Q J Nucl Med Mol Imaging; 2024 Sep; 68(3):169-175. PubMed ID: 39008330
    [Abstract] [Full Text] [Related]

  • 4. Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.
    Ruan M, Liu L, Wang L, Lei B, Sun X, Chang C, Shen Y, Xie W.
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer.
    Shi A, Wang J, Wang Y, Guo G, Fan C, Liu J.
    Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F, Wu X, Zhu J, Huang Y, Song X, Jiang L.
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [Abstract] [Full Text] [Related]

  • 7. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL.
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of cigarette smoking on metabolic activity of lung cancer on baseline 18F-FDG PET/CT.
    Jiang M, Guo X, Zhang X, Gao Q, Mei W, Zhang J, Zheng J.
    PeerJ; 2022 Nov; 10():e13352. PubMed ID: 35497180
    [Abstract] [Full Text] [Related]

  • 10. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, Chen T, Yang J, Jing M, Chen F, Wang C, Sun H, Huang Y.
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [Abstract] [Full Text] [Related]

  • 11. The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis.
    Guo Y, Zhu H, Yao Z, Liu F, Yang D.
    Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472
    [Abstract] [Full Text] [Related]

  • 12. Value of interim 18F-FDG PET/CT for predicting progression-free survival in stage ⅢB/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
    Shao D, Cheng Y, Yuan ZS, Jiang BY, Wang SX.
    Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
    [Abstract] [Full Text] [Related]

  • 13. Metabolic tumor volume derived from 18F-FDG PET/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients.
    Ding C, Mao X, Li N, Huang M, Huang Z, Bao W, Li H, Fan J.
    Hell J Nucl Med; 2022 Nov; 25(1):63-70. PubMed ID: 35503557
    [Abstract] [Full Text] [Related]

  • 14. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
    Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X.
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [Abstract] [Full Text] [Related]

  • 15. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
    Nair JKR, Saeed UA, McDougall CC, Sabri A, Kovacina B, Raidu BVS, Khokhar RA, Probst S, Hirsh V, Chankowsky J, Van Kempen LC, Taylor J.
    Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 17. The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.
    Wang L, Ruan M, Lei B, Yan H, Sun X, Chang C, Liu L, Xie W.
    Lung Cancer; 2020 Dec; 150():44-52. PubMed ID: 33065462
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.